Immunotherapy company Arbele banking on cadherin-17 as target for gastrointestinal cancers

Oct. 10, 2023

Arbele Ltd. founder and CEO John Luk identified and patented cadherin-17 as a therapeutic cancer target, and the company was founded to develop immunotherapies for gastrointestinal cancers, which are prevalent in Asia Pacific.

BioWorld BioWorld Asia Newco news Cancer Australia China

Today's news in brief

BioWorld

BioWorld briefs for Nov. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 11, 2025.

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld Science

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...

Lilly moves deeper into RNAi with $1.2B Sanegene obesity deal

BioWorld

In a deal worth $1.2 billion, Suzhou Sanegene Bio Inc. and Eli Lilly and Co. are partnering to advance RNAi candidates for metabolic diseases based on Sanegene's...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...